Pharmaceutical services in a Mexican pain relief and palliative care institute

Fuente: Redalyc
Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Jéssica Gutiérrez Godínez
Format: Artículo científico
Sprache:en
Veröffentlicht: Centro de investigaciones y Publicaciones Farmacéuticas 2007
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1876429963100422144
author Jéssica Gutiérrez Godínez
author_facet Jéssica Gutiérrez Godínez
contents Pharmaceutical services in a Mexican pain relief and palliative care institute Jéssica Gutiérrez Godínez Raymundo Escutia Gutiérrez César R. Cortéz Álvarez Rosa Margarita Álvarez Álvarez Jorge LV. Flores Hernández José G. López y López. Medicina Mexico Drug Toxicity Adverse Drug Reaction Reporting Systems Neither the purchase nor the distribution ofpharmaceuticals in hospitals and communitypharmacies in Mexico is under the care ofpharmacists. Some are under control of physicians.This report presents the results of theimplementation of somef pharmaceutical servicesfor the Jalisco Pain Relief, and Palliative CareInstitute (Palia Institute), under the direction of theSecretary of Health, Government of Jalisco. Theservices implemented were drug distributionsystem, Drug Information Service,Pharmacovigilance Program , and homepharmacotherapy follow-up pilot program forpatients with advanced illness, with the ultimateusing the appropriate medication. The drugdistribution system included dispensing of opioidpain medications, antidepressants, anticonvulsants,NSAIDs, anxiolytic drugs, steroid drugs, laxatives,and anti-emetics. The frequently used drugs weremorphine sulfate (62%), amitriptyline (6.4%), anddextropropoxyphene (5.8%). The Drug InformationService answered 114 consultations, mainly askedby a physician (71%) concerned with adverse drugreactions and contraindications (21%). Thepharmacovigilance program identified 146suspected adverse drug reactions and classifiedthem reasonably as possible (27%), probable(69%), and certain (4%). These were attributedmainly to pregabalin and tramadol. The homepharmacotherapy follow-up pilot program caredpatients with different cancer diagnoses and drugrelatedproblems (DRP), which were identified andclassified (according to second GranadaConsensus) for pharmaceutical intervention as DRP 1 (5%), DRP 2 (10%), DRP 3 (14%), DRP 4 (19%),DRP 5 (24%), or DRP 6 (28%).This report provides information concerning theaccurate use of medication and, above all, anopportunity for Mexican pharmacists to become anpart of health teams seeking to resolve drug-relatedproblems. 2007 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69050406 https://www.redalyc.org/journal/690/69050406/ https://www.redalyc.org/journal/690/69050406/html/ https://www.redalyc.org/journal/690/69050406/69050406.epub https://www.redalyc.org/journal/690/69050406/movil en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.4 Vol.5
format Artículo científico
id redalyc_69050406
institution Redalyc
language en
publishDate 2007
publisher Centro de investigaciones y Publicaciones Farmacéuticas
spellingShingle Pharmaceutical services in a Mexican pain relief and palliative care institute
Jéssica Gutiérrez Godínez
Medicina
Mexico
Drug Toxicity
Adverse Drug Reaction Reporting Systems
Pharmaceutical services in a Mexican pain relief and palliative care institute Jéssica Gutiérrez Godínez Raymundo Escutia Gutiérrez César R. Cortéz Álvarez Rosa Margarita Álvarez Álvarez Jorge LV. Flores Hernández José G. López y López. Medicina Mexico Drug Toxicity Adverse Drug Reaction Reporting Systems Neither the purchase nor the distribution ofpharmaceuticals in hospitals and communitypharmacies in Mexico is under the care ofpharmacists. Some are under control of physicians.This report presents the results of theimplementation of somef pharmaceutical servicesfor the Jalisco Pain Relief, and Palliative CareInstitute (Palia Institute), under the direction of theSecretary of Health, Government of Jalisco. Theservices implemented were drug distributionsystem, Drug Information Service,Pharmacovigilance Program , and homepharmacotherapy follow-up pilot program forpatients with advanced illness, with the ultimateusing the appropriate medication. The drugdistribution system included dispensing of opioidpain medications, antidepressants, anticonvulsants,NSAIDs, anxiolytic drugs, steroid drugs, laxatives,and anti-emetics. The frequently used drugs weremorphine sulfate (62%), amitriptyline (6.4%), anddextropropoxyphene (5.8%). The Drug InformationService answered 114 consultations, mainly askedby a physician (71%) concerned with adverse drugreactions and contraindications (21%). Thepharmacovigilance program identified 146suspected adverse drug reactions and classifiedthem reasonably as possible (27%), probable(69%), and certain (4%). These were attributedmainly to pregabalin and tramadol. The homepharmacotherapy follow-up pilot program caredpatients with different cancer diagnoses and drugrelatedproblems (DRP), which were identified andclassified (according to second GranadaConsensus) for pharmaceutical intervention as DRP 1 (5%), DRP 2 (10%), DRP 3 (14%), DRP 4 (19%),DRP 5 (24%), or DRP 6 (28%).This report provides information concerning theaccurate use of medication and, above all, anopportunity for Mexican pharmacists to become anpart of health teams seeking to resolve drug-relatedproblems. 2007 artículo científico 1885-642X https://www.redalyc.org/articulo.oa?id=69050406 https://www.redalyc.org/journal/690/69050406/ https://www.redalyc.org/journal/690/69050406/html/ https://www.redalyc.org/journal/690/69050406/69050406.epub https://www.redalyc.org/journal/690/69050406/movil en http://www.redalyc.org/revista.oa?id=690 Pharmacy Practice application/pdf Centro de investigaciones y Publicaciones Farmacéuticas Pharmacy Practice (España) Num.4 Vol.5
title Pharmaceutical services in a Mexican pain relief and palliative care institute
topic Medicina
Mexico
Drug Toxicity
Adverse Drug Reaction Reporting Systems
url https://www.redalyc.org/articulo.oa?id=69050406
https://www.redalyc.org/journal/690/69050406/
https://www.redalyc.org/journal/690/69050406/html/
https://www.redalyc.org/journal/690/69050406/69050406.epub
https://www.redalyc.org/journal/690/69050406/movil